Effect of Pectin in Chronic Kidney Disease Patients ( Stage 3 and 4 )

Phase 2

Not yet recruiting

• Conditions: Chronic Kidney Diseases
• Interventions: Drug: Pectin

• Registration Number: NCT06531993
• Lead Sponsor: Assiut University

Brief Summary

Effect of pectin in chronic kidney disease patients

Detailed Description

Chronic kidney disease (CKD) is a serious global health problem leading to serious comorbidities, end-stage renal disease (ESRD), and death

From 1990 to 2016, the prevalence of CKD increased by 90% worldwide, which is closely tied to the increase in at-risk populations with diabetes mellitus (DM), hypertension (HTN), and prediabetes . It is estimated to be around 9.1 to 13.4%. This means there are about 700 million to over 800 million cases of CKD worldwide.

In 2017, CKD resulted in 1.2 million deaths and was the 12th leading cause of death worldwide . And in the same year, the estimated prevalence of CKD in Egypt was 7.1 million individuals, which means 106 patients/1000 population .

Pectin, a class of heteropolysaccharides based on polygalacturonic acid, is a safe and non-toxic natural food additive recommended by the Joint FAO/WHO Committee on Food Additives with no daily additive limit . Pectin is mainly obtained from apple pomace, citrus peels and sugar beets, ancurrently, commercial pectin contains ≥65% Gal-A (galacturonic acid).

Among the patients who tried to take the pectin, unexpectedly was found that the pectin had a significant effect on the rapid reduction of blood creatinine concentration in patients with chronic kidney disease. So, the authors followed up the physical examination indeces of chronic kidney disease patients who took the Pectin .

Study Timeline

• Study First Submitted: 2024-06-10
• Status Verified: 2024-07
• Study First Submitted QC: 2024-07-27
• Last Update Submitted: 2024-07-27
• Study Start: 2024-08
• Study First Posted: 2024-08-01
• Last Update Posted: 2024-08-01
• Primary Completion: 2025-03
• Study Completion: 2025-08

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 98

Inclusion Criteria

1. Clinical diagnosis of CKD patients (stage 3 and 4)
2. age between 18 and 60 years
3. Must be able to swallow tablets

Exclusion Criteria

1- End stage renal disease ( stage 5 ) 2 - Patients with renal transplantation 3- pregnancy 4- Presence of malignancy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placepo group	Pectin	Standard of care
Pectin group	Pectin	Pectin treatment

Primary Outcome Measures

Name	Time	Method
effect of pectin in GFR improvement in ckd patients	6 month	Measure eGFR using CKD epi equation,